187 related articles for article (PubMed ID: 12152983)
1. Induction of immunologic tolerance for allogeneic hematopoietic cell transplantation.
Appleman LJ; Tzachanis D; Grader-Beck T; Van Puijenbroek AA; Boussiotis VA
Leuk Lymphoma; 2002 Jun; 43(6):1159-67. PubMed ID: 12152983
[TBL] [Abstract][Full Text] [Related]
2. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
3. Complete blockade of B7 family-mediated costimulation is necessary to induce human alloantigen-specific anergy: a method to ameliorate graft-versus-host disease and extend the donor pool.
Gribben JG; Guinan EC; Boussiotis VA; Ke XY; Linsley L; Sieff C; Gray GS; Freeman GJ; Nadler LM
Blood; 1996 Jun; 87(11):4887-93. PubMed ID: 8639863
[TBL] [Abstract][Full Text] [Related]
4. Immunologic tolerance for immune system-mediated diseases.
Hackett CJ; Dickler HB
J Allergy Clin Immunol; 1999 Mar; 103(3 Pt 1):362-70. PubMed ID: 10069866
[TBL] [Abstract][Full Text] [Related]
5. Human CD34(+) blood cells induce T-cell unresponsiveness to specific alloantigens only under costimulatory blockade.
Arpinati M; Terragna C; Chirumbolo G; Rizzi S; Urbini B; Re F; Tura S; Baccarani M; Rondelli D
Exp Hematol; 2003 Jan; 31(1):31-8. PubMed ID: 12543104
[TBL] [Abstract][Full Text] [Related]
6. Blocking CD40 - CD154 and CD80/CD86 - CD28 interactions during primary allogeneic stimulation results in T cell anergy and high IL-10 production.
Van Gool SW; Vermeiren J; Rafiq K; Lorr K; de Boer M; Ceuppens JL
Eur J Immunol; 1999 Aug; 29(8):2367-75. PubMed ID: 10458748
[TBL] [Abstract][Full Text] [Related]
7. Helper T cell anergy: from biochemistry to cancer pathophysiology and therapeutics.
Appleman LJ; Tzachanis D; Grader-Beck T; van Puijenbroek AA; Boussiotis VA
J Mol Med (Berl); 2001; 78(12):673-83. PubMed ID: 11434720
[TBL] [Abstract][Full Text] [Related]
8. Cutting edge: the relative distribution of T cells responding to chemically dominant or minor epitopes of lysozyme is not affected by CD40-CD40 ligand and B7-CD28-CTLA-4 costimulatory pathways.
DiPaolo RJ; Unanue ER
J Immunol; 2002 Sep; 169(6):2832-6. PubMed ID: 12218093
[TBL] [Abstract][Full Text] [Related]
9. Hematopoietic stem cell graft manipulation as a mechanism of immunotherapy.
Talmadge JE
Int Immunopharmacol; 2003 Aug; 3(8):1121-43. PubMed ID: 12860168
[TBL] [Abstract][Full Text] [Related]
10. Non-myeloablative hematopoietic stem cell transplantation (NST) in the treatment of human malignancies: from animal models to clinical practice.
Shimoni A; Nagler A
Cancer Treat Res; 2002; 110():113-36. PubMed ID: 11908195
[TBL] [Abstract][Full Text] [Related]
11. Differential graft-versus-leukaemia effect by CD28 and CD40 co-stimulatory blockade after graft-versus-host disease prophylaxis.
Ohata J; Sakurai J; Saito K; Tani K; Asano S; Azuma M
Clin Exp Immunol; 2002 Jul; 129(1):61-8. PubMed ID: 12100023
[TBL] [Abstract][Full Text] [Related]
12. Non-myeloablative transplants for malignant disease.
Storb RF; Champlin R; Riddell SR; Murata M; Bryant S; Warren EH
Hematology Am Soc Hematol Educ Program; 2001; ():375-91. PubMed ID: 11722994
[TBL] [Abstract][Full Text] [Related]
13. New developments in allotransplant immunology.
Barrett AJ; Rezvani K; Solomon S; Dickinson AM; Wang XN; Stark G; Cullup H; Jarvis M; Middleton PG; Chao N
Hematology Am Soc Hematol Educ Program; 2003; ():350-71. PubMed ID: 14633790
[TBL] [Abstract][Full Text] [Related]
14. CD4(+)CD25(+) immune regulatory cells are required for induction of tolerance to alloantigen via costimulatory blockade.
Taylor PA; Noelle RJ; Blazar BR
J Exp Med; 2001 Jun; 193(11):1311-8. PubMed ID: 11390438
[TBL] [Abstract][Full Text] [Related]
15. Blockade of CD28-B7, but not CD40-CD154, prevents costimulation of allogeneic porcine and xenogeneic human anti-porcine T cell responses.
Lee RS; Yamada K; Womer KL; Pillsbury EP; Allison KS; Marolewski AE; Geng D; Thall AD; Arn JS; Sachs DH; Sayegh MH; Madsen JC
J Immunol; 2000 Mar; 164(6):3434-44. PubMed ID: 10706740
[TBL] [Abstract][Full Text] [Related]
16. Induction of donor-specific T cell anergy by portal venous injection of allogeneic cells.
Sugiura K; Kato K; Hashimoto F; Jin T; Amoh Y; Yamamoto Y; Morita H; Okumura K; Ikehara S
Immunobiology; 1997 Nov; 197(5):460-77. PubMed ID: 9413746
[TBL] [Abstract][Full Text] [Related]
17. CD40 signaling replaces CD4+ lymphocytes and its blocking prevents chronic rejection of heart transplants.
Fischbein MP; Ardehali A; Yun J; Schoenberger S; Laks H; Irie Y; Dempsey P; Cheng G; Fishbein MC; Bonavida B
J Immunol; 2000 Dec; 165(12):7316-22. PubMed ID: 11120867
[TBL] [Abstract][Full Text] [Related]
18. Induction of alloantigen-specific anergy in human peripheral blood mononuclear cells by alloantigen stimulation with co-stimulatory signal blockade.
Davies JK; Barbon CM; Voskertchian AR; Nadler LM; Guinan EC
J Vis Exp; 2011 Mar; (49):. PubMed ID: 21445041
[TBL] [Abstract][Full Text] [Related]
19. Involvement of CD40 ligand-CD40 and CTLA4-B7 pathways in murine acute graft-versus-host disease induced by allogeneic T cells lacking CD28.
Saito K; Sakurai J; Ohata J; Kohsaka T; Hashimoto H; Okumura K; Abe R; Azuma M
J Immunol; 1998 May; 160(9):4225-31. PubMed ID: 9574523
[TBL] [Abstract][Full Text] [Related]
20. B7 interactions with CD28 and CTLA-4 control tolerance or induction of mucosal inflammation in chronic experimental colitis.
Liu Z; Geboes K; Hellings P; Maerten P; Heremans H; Vandenberghe P; Boon L; van Kooten P; Rutgeerts P; Ceuppens JL
J Immunol; 2001 Aug; 167(3):1830-8. PubMed ID: 11466409
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
